CTI Life Sciences Fund L.P. — Full Portfolio

Profound Medical develops real-time MRI-guided thermal ultrasound systems for incision-free ablation of abnormal or cancerous tissue.

BiotechDeep TechHealthtechMedical DevicesMississauga

Arun Menawat(CEO and Chairman of the Board)inRashed Dewan(Executive Officer)Mathieu Burtnyk(Chief Operating Officer)

BoardJean-Francois Pariseau(Director)Damian Lamb(Director)William Curran(Director)

Co-investorsFACIT (Fight Against Cancer Innovation Trust)Genesys Capital

Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques.

BiotechHealthtech

Grant Pickering(Founder)in

Co-investorsBioRock VenturesForesite CapitalFrazier Life SciencesLongitude CapitalRA Capital

Thryv Therapeutics is a clinical-stage biotechnology company developing selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) for inherited cardiac arrhythmias such as Long QT Syndrome and acquired cardiometabolic diseases.

BiotechHealthtechMedical Devices

Paul F. Truex(Chairman of the Board & Chief Executive Officer)Debra OdinkinAmy Sehnertin

Co-investorsAmzak HealthadMare BioInnovationsAlexandriaLumira Ventures

Oligon Therapeutics develops RNA-based multi-targeting drugs using its SeekR platform, which combines RNA aptamer oligo-binders with siRNA silencers into a single self-delivering molecule for precise targeting of specific cell types, including T-cells and cancer cells.

AI & Machine LearningBiotech

Thryv Therapeutics is a clinical-stage biotech developing precision-medicine treatments for genetic arrhythmia syndromes and acquired cardiometabolic diseases using selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1).

BiotechDigital HealthMedical Devices

Paul F. Truex(Chairman of the Board & Chief Executive Officer)Debra Odink(President & Chief Development Officer)inAmy Sehnert(Chief Medical Officer)inMatt Killeen(Chief Business Officer)

BoardSaumya Das(Chief Scientific Advisor)

Co-investorsLumira VenturesadMare BioInnovationsAmzak HealthFonds de solidarité FTQ

AbilityPharma develops innovative oncology therapies that induce autophagy to treat various cancers and address unmet medical needs.

BiotechDigital HealthHealthtechMedical DevicesGirona, ES

Co-investorsCapital Cell

Clinical-stage biotherapeutics company developing mTORC1-specific inhibitors.

Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism.

BiotechBerkeley, US

Allison J. Hulme(CEO & President)John Kincaid(Chief Scientific Officer)Davis Ryman(Executive Officer)Micah Zajic(Executive Officer)Ian Massey(Executive Officer)Stelios Tzannis(Executive Officer, Director)

Co-investorsCoastCapFJ LabsSofinnova VenturesvenBio PartnersvenBio Global Strategic

Co-investorsAndera PartnersEQT Life SciencesKurma PartnersLSP (Life Sciences Partners)Sofinnova Partners

Apollo is a venture capital firm that invests in life-science and biotechnology startups, combining entrepreneurial expertise with deep scientific knowledge to support early-stage companies in drug development and personalized medicine.

BiotechDeep TechHealthtechLongevity

Nils Regge(Co-Founder & General Partner)in

Co-investorsBLN CapitalCoastCapFJ LabsKfW CapitalTruVenturo GmbHForesite Capital+3 more

Precision cardiology company built around a Phase 3-ready asset from the Montreal Heart Institute.

Domain Therapeutics is a clinical-stage biopharmaceutical company developing GPCR-targeting therapies to address unmet medical needs in immuno-oncology and inflammation.

BiotechDigital Health

Co-investors3B Future Health Fund

enGene is a genetic medicine company developing drug therapies across oncology, urology, and other therapeutic areas, with a focus on patient outcomes.

BiotechMedical Devices

Co-investorsLumira Ventures

Epitopea develops off-the-shelf cancer vaccines targeting aberrantly expressed tumor-specific antigens using its proprietary CryptoMap platform.

AI & Machine LearningBiotechHealthtechMontreal, CA

Claude PerreaultPierre Thibault

Co-investorsAdvent Life SciencesCambridge Innovation CapitaladMare BioInnovationsFonds de solidarité FTQ

Find Therapeutics is a clinical-stage biopharmaceutical company developing therapies to treat demyelinating diseases, particularly multiple sclerosis and related conditions affecting myelin repair.

BiotechLongevityMedical DevicesMontreal, CA

Co-investorsadMare BioInnovations

Developing therapies for congenital disorders of glycosylation combining replacement therapies with intracellular delivery vehicles.

BiotechSan Francisco, US

Agnes Rafalko(Executive Officer, Director)

BoardPeter C.M. McWilliams(Director)Giacomo Chiesi(Director)Christopher Starr(Director)

Co-investorsAdvent Life SciencesChiesi VenturesRemiges Ventures, Inc.RiverVest Venture PartnersSanderling VenturesSanofi Ventures

BiotechDartmouth

James Hall(Director)Julia P. Gregory(Director)Wayne Pisano(Director)Markus Warmuth(Director)Andrew Sheldon(Director)Pierre Labbe(Executive Officer)

Platform producing potential best-in-class assets against GPCR targets with strong pre-clinical data.

Co-investorsYaletown Partners

Phenomic AI is a biotech company developing therapies for solid tumors using a machine-learning-powered transcriptomics platform that analyzes single-cell RNA data to identify drug targets and understand tumor biology.

AI & Machine LearningBiotechDeep TechToronto, CA

Sam Cooper(Co-founder & CTO)Oren Kraus(Co-founder)in

Co-investorsCantos VenturesAV8 VenturesGarage CapitalHemi Ventures, LlcToronto Innovation Acceleration PartnersHike Ventures+1 more

MRI-guided ablation improving survival outcomes with a less invasive approach than traditional methods.

A URL shortcut operated by Google that directs users to official Google products and services.

Co-investorsFirst Bight VenturesSwanlaab Venture FactoryAbstract VenturesGeneral CatalystUnion Square Ventures (USV)Y Combinator

First-in-class treatment for the rare pediatric cardiology disease Long QT Syndrome, with strong Phase 2a efficacy.

Co-investorsPfizer Venture InvestmentsSofinnova Partners

Hierotope platform for precision biologics; acquired by Otsuka.

Co-investorsCycad Group LLCLux CapitalMRL Ventures Fund

BiotechWaltham, US

Garry Nicholson(Executive Officer, Director)Edward Freedman(Executive Officer)Rakesh Jain(Director)

BoardRobert Langer(Director)David Mott(Director)Alan Crane(Director)

Co-investorsPolaris Partners